A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA. (12th June 2019) - Wang, M.; Belada, D.; Cheah, C.; Chu, M.P.; Dreyling, M.; Flinn, I.; Fogliatto, L.; Goy, A.; Inwards, D.; Jurczak, W.; Mayer, J.; Re, F.; et al.